Uridine - Repligen

Drug Profile

Uridine - Repligen

Alternative Names: RG 2417

Latest Information Update: 27 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator McLean Hospital; Repligen
  • Developer Repligen Corporation
  • Class Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Bipolar disorders; Neurodegenerative disorders
  • Discontinued Epilepsy

Most Recent Events

  • 08 Mar 2011 Top-line efficacy and tolerability data from a phase IIb trial in Bipolar disorders released by Repligen
  • 13 Jan 2011 Repligen completes a phase IIb trial for Bipolar disorders in USA
  • 01 Oct 2010 Repligen completes enrolment in a phase IIb trial in Bipolar disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top